ClinicalTrials.Veeva

Menu

Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment (MISSION)

R

Radboud University Medical Center

Status

Not yet enrolling

Conditions

Mycophenolic Acid
Area Under Curve
Tacrolimus
Immunosuppressive Agents
Pharmacokinetics

Treatments

Other: venipuncture

Study type

Observational

Funder types

Other

Identifiers

NCT06095895
NL85390.091.23

Details and patient eligibility

About

This is a prospective observational study of MIPD in clinical practice for paediatric kidney transplant patients using tacrolimus and mycophenolic acid in Radboudumc. Dose individualization in paediatric kidney transplant patients using the InsightRX platform is performed as standard care, meaning that a pharmacokinetic model and drug levels measured at t=0, t=1 and t=2 hours will be used to calculate the exposure. Based on the estimated exposure, the pharmacist gives a dose recommendation to the physician, who can then modify the dosage of mycophenolic acid or tacrolimus. The selected dose and the measured MPA and tacrolimus concentrations will be used to predict the future exposure. A second exposure measurement will be performed to evaluate whether our model is able to predict future exposure.

Enrollment

30 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Kidney transplant patients using tacrolimus and/or mycophenolic acid
  • Age between 0 and 18 years
  • Indication for an AUC measurement - judgement of clinician

Exclusion criteria

  • Incapacitated patients
  • No informed consent
  • Not proficient in the Dutch language

Trial contacts and locations

0

Loading...

Central trial contact

Astrid Heida, Msc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems